Stonepine Capital Management, LLC Iveric Bio, Inc. Transaction History

Stonepine Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$7.07 - $17.5 $3.66 Million - $9.06 Million	-517,445 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$5.69 - $7.17 $2.04 Million - $2.56 Million	-357,735 Reduced 40.88%	517,445 $3.27 Million
Q1 2021 May 14, 2021	BUY	$5.08 - $6.89 $381,914 - $517,990	75,180 Added 9.4%	875,180 $5.41 Million
Q4 2020 Feb 12, 2021	SELL	$5.65 - $7.66 $8.83 Million - $12 Million	-1,562,240 Reduced 66.13%	800,000 $5.53 Million
Q3 2020 Nov 13, 2020	SELL	$4.01 - $6.29 $1.51 Million - $2.37 Million	-377,401 Reduced 13.78%	2,362,240 $13.3 Million
Q2 2020 Aug 13, 2020	BUY	$3.06 - $6.6 $476,916 - $1.03 Million	155,855 Added 6.03%	2,739,641 $14 Million
Q1 2020 May 14, 2020	SELL	$2.83 - $8.44 $1.18 Million - $3.51 Million	-416,214 Reduced 13.87%	2,583,786 $8.89 Million
Q4 2019 Feb 13, 2020	SELL	$0.93 - $8.58 $768,089 - $7.09 Million	-825,903 Reduced 21.59%	3,000,000 $25.7 Million
Q3 2019 Nov 13, 2019	SELL	$1.09 - $1.29 $313,504 - $371,028	-287,619 Reduced 6.99%	3,825,903 $4.29 Million
Q2 2019 Aug 13, 2019	BUY	$1.21 - $1.48 $4.98 Million - $6.09 Million	4,113,522 New	4,113,522 $5.35 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Stonepine Capital Management, LLC with notifications on news.